Sugar Maple Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.2M Sell
56,269
-198
-0.4% -$42.6K 9.13% 1
2026
Q1
$12.3M Sell
56,467
-131
-0.2% -$29.1K 7.45% 3
2025
Q4
$12.9M Sell
56,598
-1
-0% -$228 8.69% 2
2025
Q3
$13.1M Sell
56,599
-49
-0.1% -$9.98K 9.37% 1
2025
Q2
$10.5M Sell
56,648
-77
-0.1% -$14.3K 8.2% 3
2025
Q1
$11.9M Buy
56,725
+27
+0% +$5.25K 9.36% 2
2024
Q4
$10.1M Buy
56,698
+140
+0.2% +$25.7K 7.67% 2
2024
Q3
$11.2M Buy
56,558
+207
+0.4% +$38.6K 9.7% 2
2024
Q2
$9.67M Sell
56,351
-9,010
-14% -$1.49M 9.35% 2
2024
Q1
$11.9M Buy
+65,361
New +$11.3M 11.48% 2

Other funds holding ABBV

Sugar Maple Asset Management's ABBV Position: Q2 2026 in Review

Sugar Maple Asset Management reduced its AbbVie (ABBV) stake by 0.35% in Q2 2026, selling an estimated $42.6K and leaving 56,269 shares worth $14.2M. The position accounts for 9.13% of the portfolio, ranked #1.

Sugar Maple Asset Management first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sugar Maple Asset Management held 56,269 shares of AbbVie worth $14.2M as of Q2 2026.
  • Sugar Maple Asset Management sold 198 AbbVie shares in Q2 2026, an estimated $42.6K.
  • AbbVie made up 9.13% of Sugar Maple Asset Management's portfolio in Q2 2026, its #1 holding.
  • Sugar Maple Asset Management first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sugar Maple Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.